Displaying drugs 7801 - 7825 of 8028 in total
6-amino-4-(2-phenylethyl)-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one
6-amino-4-(2-phenylethyl)-1,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one is a solid. This compound belongs to the stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids. It is known to target...
Experimental
Matched Description: … The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids. …
Famprofazone
Famprofazone is a nonsteroidal anti-inflammatory agent found in combination products such as ‘Gewodin’ which is marketed in Taiwan. It is important to note that the drug is metabolized to methamphetamine and amphetamine in the body and can lead to positive tests results for illicit drug use.[A236369,L34724] Famprofazone is included in...
Experimental
Matched Description: … [A236369,L34724] Famprofazone is included in the list of prohibited substances specified by the ‘World …
UCB7362
UCB7362 is an orally active plasmepsin X (PMX) inhibitor currently investigated for the treatment of malaria. Plasmepsins are aspartyl proteases produced by the malaria parasite Plasmodium falciparum, and PMX is considered to be essential for parasite egress and invasion. UCB7362 is estimated to achieve a significant reduction in asexual blood-stage...
Investigational
Matched Description: … UCB7362 is an orally active plasmepsin X (PMX) inhibitor currently investigated for the treatment of …
Virus Specific T-Cell
Virus Specific T-Cells (VSTs) are a target therapy that are generated for specific viral antigens. These products are generated from virus-naive or virus-experienced autologous or allogenic sources. Antigens identified as an immune target are presented by antigen-presenting cells (APCs) to T-cells along with other molecules that stimulate their growth and...
Investigational
Matched Description: … In some cases, the cells are created from blood samples of patients who have recovered from viral infections …
CoronaVac
CoronaVac, previously known as PiCoVacc, is a SARS-CoV-2 purified, inactivated, and adsorbed vaccine candidate developed by SinoVac Biotech Corporation . It was developed by propagating the SARS-CoV-2 CN2 strain inside Vero Cells and inactivating it with B-propiolactone[A219481;A219758]. In preclinical trials, PiCoVacc induced SARS-CoV-2-specific neutralizing antibodies in rats, mice, and the...
Investigational
Matched Description: … As of August 2020, the vaccine is being tested in numerous human clinical trials assessing its safety …
EGS21
EGS21(TM) is a beta-D-glucosylceramide (GC) compound. It is a potential therapeutic for treating immune mediated disorders. GC is a glycolipid that has been shown by Enzo scientists and collaborators to act as an anti-inflammatory agent in animal model systems, and therefore is being evaluated as an important candidate drug in...
Investigational
Matched Description: … systems, and therefore is being evaluated as an important candidate drug in the treatment of …
FINLAY-FR-1
FINLAY-FR-1, also known as Soberana 01, is a vaccine candidate for COVID-19 that is being led developmentally by the Finlay Vaccine Institute . It is currently being tested in the clinical trial RPCEC00000332 (Phase I / II, randomized, controlled, adaptive, double-blind and multicenter study to evaluate the safety, reactogenicity and...
Investigational
Matched Description: … adaptive, double-blind and multicenter study to evaluate the safety, reactogenicity and immunogenicity, of …
Bevirimat
Bevirimat, also known as PA-457 or YK-FH312, is investigated in clinical trials for treating HIV infection. Bevirimat is a solid. This compound belongs to the androgens and derivatives, which are hydroxylated C19 steroid hormones. They are known to favour the development of masculine characteristics. They also show profound effects on...
Investigational
Matched Description: … They are known to favour the development of masculine characteristics. …
Fasinumab
Fasinumab is a human IgG1k monoclonal antibody targeted against nerve growth factor (NGF). It is currently under investigation for the treatment osteoarthritic pain and has demonstrated significantly greater pain relief and functional improvement as compared to standard therapy (i.e. NSAIDs and/or opioids) in this patient population. NGF was first discovered...
Investigational
Matched Description: … role in nociceptive signaling transduction and has thus become an attractive target in the treatment of …
TMC-310911
TMC-310911 (also known as ASC-09) is a novel investigational protease inhibitor (PI) that is structurally similar to the currently available darunavir. It is being investigated for use in HIV-1 infections. TMC-310911 has shown marked activity against a variety of HIV-1 strains, including multi-PI-resistant strains, and may be less likely to...
Investigational
Matched Description: … TMC-310911 has shown marked activity against a variety of HIV-1 strains, including multi-PI-resistant …
IMM-101
IMM-101 is a heat-inactivated immune-activating mycobacterial product. It has shown to be safe and well tolerated to complement conventional cancer therapy for patients with melanoma and pancreatic ductal adenocarcinoma[A220013,A220018,A220023]. Studies with IMM-101 showed the vaccine’s ability to stimulate cancer patients’ immune systems to help kill cancer cells. As of July...
Investigational
Matched Description: … As of July 2020, researchers from the Ottawa Hospital and Queen’s University, in partnership with the …
Otelixizumab
Otelixizumab is a monoclonal antibody that binds to a receptor found on all T cells called CD3, which is involved in normal T cell signaling. Otelixizumab is believed to inhibit the function of autoreactive T cells, which are important in propagating autoimmune diseases, while inducing regulatory T cell pathways that...
Investigational
Matched Description: … Otelixizumab is believed to inhibit the function of autoreactive T cells, which are important in propagating …
Rivanicline
Rivanicline (TC-2403, RJR-2403, (E)-metanicotine) is a partial agonist at neuronal nicotinic acetylcholine receptors, binding primarily to the α4β2 subtype. It was originally developed as a potential treatment for Alzheimer's disease for its nootropic effects but has also been found to inhibit the production of Interleukin-8. It has subsequently been developed...
Investigational
Matched Description: … for Alzheimer's disease for its nootropic effects but has also been found to inhibit the production of …
Diazepinomicin
Diazepinomicin has been used in trials studying the treatment of Glioblastoma Multiforme. It is a proprietary first-in-class small molecule with the potential to treat multiple solid tumours like the well known chemotherapeutics, doxorubicin and mitomycin C. Diazepinomicin is a natural product derived from a non-pathogenic micro-organism. Discovered using Thallion’s DECIPHER...
Investigational
Matched Description: … Diazepinomicin has been used in trials studying the treatment of Glioblastoma Multiforme. …
AVR-RD-02
AVR-RD-02 is an investigational ex vivo lentiviral gene therapy developed by AVROBIO Inc. It consists of autologous CD34+ enriched hematopoietic stem cells (HSCs) that have been genetically modified ex vivo with a lentiviral vector (LV) to contain a ribonucleic acid (RNA) transcript that, after reverse transcription, results in codon-optimized, complementary...
Investigational
Matched Description: … It consists of autologous CD34+ enriched hematopoietic stem cells (HSCs) that have been genetically modified …
CA4P
CA4P has been shown in the laboratory to shut down the blood supply to tumours. It is one of the first vascular targeting drugs to be tested in patients. This drug was originally isolated from the African Bush Willow. The first studies in patients with this drug were aimed at...
Investigational
Matched Description: … It is one of the first vascular targeting drugs to be tested in patients. …
MDX-018
MDX-018, also known as HuMax-Inflam, is a fully human antibody that is directed to IL-8 (interleukin-8) and may have potential application in oncology and inflammation. Trials will initially focus on studies to treat glioblastoma, a cancer of the central nervous system. Other possible indications include chronic obstructive pulmonary disease (COPD)...
Investigational
Matched Description: … Trials will initially focus on studies to treat glioblastoma, a cancer of the central nervous system. …
rhGAD65
rhGAD65 (recombinant human glutamic acid decarboxylase) is a vaccine being developed to treat insulin dependent type 1 diabetes.
Investigational
Human umbilical cord blood mononuclear cell-conditioned medium
Transplantation with human umbilical cord blood mononuclear cells (HUCBC) has demonstrated promising results in various disease states. While some of the positive results are credited to HUCBCs’ differentiation potential, the growth factors and cytokines these cells secrete are also implicated. When HUCBCs secrete growth factors and anti-inflammatory cytokines, they are...
Investigational
Matched Description: … While some of the positive results are credited to HUCBCs’ differentiation potential, the growth factors …
IMM101
IMM-101 is a heat-inactivated immune-activating mycobacterial product. It has shown to be safe and well tolerated to complement conventional cancer therapy for patients with melanoma and pancreatic ductal adenocarcinoma [PMID: 21930686; PMID: 30107850; PMID: 27599039]. Studies with IMM-101 showed the vaccine’s ability to stimulate cancer patients’ immune systems to help...
Investigational
Matched Description: … As of July 2020, researchers from the Ottawa Hospital and Queen’s University, in partnership with the …
Sugemalimab
Sugemalimab is a fully human, full-length IgG4 monoclonal anti-PD-L1 antibody discovered by CStone Pharmaceuticals and being investigated against relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma (R/R ENKTL) in adult patients and T-cell lymphoma.[L32868, L32873] It has been granted the Breakthrough Therapy Designation by the FDA to treat R/R ENKTL...
Investigational
Matched Description: … [L32868] Sugemalimab is under investigation in clinical trial NCT03802591 (A Study of CS1001 in Subjects …
Covax-19™
Covax-19™, a protein-based vaccine, was developed through partnership between APC and Vaxine. It uses an insect-cell-produced recombinant SARS-CoV-2 spike protein and Vaxine’s adjuvant, Advax-SM. This adjuvant is designed to circumvent high fevers, fatigue, and aches experienced with other vaccines using more traditional adjuvants. Covax-19™ was tested in animal studies, and...
Investigational
Matched Description: … As of June 2020, the vaccine is in Phase 1 trials to evaluate safety and immune responses (NCT04428073 …
AC-100
AC-100 is a novel synthetic peptide derived from an endogenous human protein produced by bone and dental cells (a fragment from matrix extracellular phosphoglycoprotein). It is being developed by Acologix, Inc.
Investigational
Boldenone undecylenate
Illicit
Vet approved
ATP
An adenine nucleotide containing three phosphate groups esterified to the sugar moiety. In addition to its crucial roles in metabolism adenosine triphosphate is a neurotransmitter.
Investigational
Nutraceutical
Displaying drugs 7801 - 7825 of 8028 in total